FXI levels are related to endothelial function and endothelial activation biomarkers in patients with recent acute coronary syndrome

siRNA-mediated inhibition of PCSK9 by RBD7022: a first-in-human trial to evaluate safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects alone and when added to statin treatment

High apo-CIII level correlates with poor lipid status, pro-inflammatory and fibrotic biomarker profile, and adverse cardiovascular outcome in patients with recent acute coronary syndrome

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: First-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in healthy subjects

First-in-human study to evaluate the safety, pharmacokinetics, and pharmacodynamics of RBD4059, a GalNAc-siRNA drug targeting coagulation Factor XI (FXI), in healthy subjects

Effects of a BBB-penetrating oligonucleotide drug, RBD8088, in mouse models of human glioblastoma